

# Addressing Lung Cancer Biomarker Testing Through Project ECHO

## Post-Session Resources Session 2



This document compiles some of the key resources mentioned during Session 2, [Pathways to Biomarker Testing](#). To review all publications, articles, or commentaries mentioned, we recommend reviewing the recording and PowerPoint presentation. All slides and recordings can be found [here](#).

### Case Presentation and Feedback Forum

- ✓ **Post Session Feedback Forum:** Feel free to provide additional feedback confidentially on Session 1 and or the entire ECHO Series beyond the post-session polls through this forum. [Link](#)

### Highlights of Session Resources (Literature or Resources Mentioned During the Didactic or Case Presentation)

- ✓ Race, Poverty, and Initial Implementation of Precision Medicine for Lung Cancer [Link](#)
- ✓ Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-Small Cell Lung Cancer [Link](#)
- ✓ Comprehensive genomic characterization of squamous cell lung cancers [Link](#)
- ✓ Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC [Link](#)
- ✓ Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study [Link](#)
- ✓ Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study [Link](#)
- ✓ Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer (NEJM publication for the ADAURA trial) [Link](#)
- ✓ Clinical characteristics and course of 63 patients with BRAF mutant lung cancers [Link](#)
- ✓ Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology [Link](#)
- ✓ NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer Version 4.2021-March 3, 2021 [Link](#)
- ✓ IASLC Establishes Global Molecular Database for Thoracic Malignancies: A Call for Data [Link](#)

### Tools/Resources of Potential Interest

- ✓ LUNgevity “No One Missed” Campaign: [Link](#)  
Includes patient resources, panel discussions with experts, including with our own faculty, Dr. Raymond Osarogiagbon, and many other resources.
- ✓ The Biomarker Testing Implementation Roadmap for Advanced Non-Small Cell Lung Cancer (NSCLC) by Association of Community Cancer Centers (ACCC) [Link](#)  
About the Tool: an innovative learning tool by ACCC that can help multidisciplinary cancer care teams obtain the knowledge they need to implement, expand, and sustain biomarker testing for patients with advanced NSCLC.
- ✓ 90-Minute 1.5 CME/MOC/CC/NCPD Opportunity from PeerView-Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment [Link](#)